Erasca, Inc. (ERAS) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway.
Is Erasca, Inc. stock overvalued or undervalued in 2026?
As of October 30, 2026, Erasca, Inc. (ERAS) trades at $14.35 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Erasca, Inc.
Market cap $5B · 52 weeks $2 – $22 (36 % below the high) · P/E no earnings · Dividend none · Next earnings November 11, 2026 · expected EPS $-0.13 · Closing price, Oct 30 · accounts published Aug 12.
- Valuation: P/E — (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 4 of 8 (uneven).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 0.0 %, fails.
- Market cap / Cash 14.7×, fails.
- Cash Runway 35 months, passes.
- Total Debt 0.2×, passes.
- Annual cash burn $0.34, info.
Against its peers (reference peers) — Erasca, Inc.: P/E —; EV/EBITDA —; ROIC -37.5 %; $5.0B. PTC Therapeutics, Inc. (P/E —; EV/EBITDA 29.4×; ROIC 5.7 %; $5.0B), Arcutis Biotherapeutics, Inc. (P/E 154×; EV/EBITDA 94.7×; ROIC 9.9 %; $4.0B), Ligand Pharmaceuticals Incorporated (P/E 144×; EV/EBITDA 93.2×; ROIC 2.3 %; $6.4B).
Profitability
| Return on Equity | -80.43% |
| Return on Invested Capital | -37.52% |
| Return on Assets | -66.02% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.12 |
| Current Ratio | 8.29 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 5.45 |
Price Performance
| 1 month | -2.65% |
| 3 months | -19.56% |
| Year-to-date | +285.75% |
| 1 year | +492.98% |
| 3 years | +510.64% |
| 5 years | -27.12% |
Related companies: RVMD · IDYA · TNGX · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L
Explore sector: Healthcare · Biotechnology
More sections of ERAS: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks